Innovent Biologics Inc (fra:6IB) Share Price

Company Profile

Business description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Contact
168 Dongping Street
Suzhou Industrial Park, Jiangsu
Suzhou215123
CHN
T: +86 51269566088
https://www.innoventbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,263

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,062.21	33.93	0.42%
DAX 40	23,118.15	131.33	0.57%
Dow JONES (US)	41,621.36	133.17	0.32%
FTSE 100	8,675.95	43.62	0.51%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,777.37	23.29	0.13%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,166.14	100.11	-0.82%
S&P 500	5,660.34	21.40	0.38%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%